FOV D consumables package
Material for up to 5 blocks; Designed for 3 Mice per Block Includes: -5 blades -8L D31 Dark OCT

Emit Imaging builds Cryo-Fluorescence Tomography systems and provides CFT fee-for-service research for preclinical imaging.
emitimaging.comCrawled Oct 16, 2026
Material for up to 5 blocks; Designed for 3 Mice per Block Includes: -5 blades -8L D31 Dark OCT
Material for up to 5 blocks; Designed for Large Samples or 4 mice Includes: -5 blades -12L D31 Dark OCT
Includes material for up to 25 blocks: -28L of D31 Dark OCT (medium required for cryosectioning procedure) -25 Blades for Xerra Block Molds A, B, C, D & E
Pack of 10 replacement blades for the EMIT Imaging Xerra CFT Imaging platform.
Pack of 30 replacement blades for the EMIT Imaging Xerra CFT Imaging platform.
Pack of 5 replacement blades for the EMIT Imaging Xerra CFT Imaging platform.
The page describes use cases for Cryo-Fluorescence Tomography and preclinical imaging applications that use whole-body ex vivo co-registered fluorescence and anatomical imaging.
The article describes Cryo-Fluorescence Tomography as a preclinical imaging technology that connects in vivo modalities, including PET/SPECT, MRI, FLI, and bioluminescence imaging, with downstream assays.
The article discusses how Cryo-Fluorescence Tomography can complement preclinical PET and SPECT imaging, which provide spatial and functional insights into biological processes.
The page features scientific posters presented by EMIT Imaging and its research partners at imaging and oncology conferences. The posters describe Cryo-Fluorescence Tomography and Xerra applications.
The page provides webinars, videos, publications, case studies, and posters. A featured video introduces Cryo-Fluorescence Tomography and its use in biodistribution research and imaging workflows.
EMIT Imaging, Inc. announced the appointment of Dr. Matthew Silva as its chief executive officer.
EMIT IMAGING, Inc. is collaborating with MIT Koch Institute for Integrative Cancer Research on a project to enhance its Cryo-Fluorescence Tomography technology.
The page lists EMIT Imaging announcements, collaborations, and milestones, including its collaboration with the MIT Koch Institute for Integrative Cancer Research on Cryo-Fluorescence Tomography technology.
The EMIT team has combined experience in preclinical imaging, engineering, software, and the imaging CRO industry. Matt Silva is the company's chief executive officer.
EMIT Imaging manufactures Cryo-Fluorescence Tomography systems and provides CFT services for the global bioresearch market.
The page lists a headquarters and CFT services lab in Natick, MA, and engineering and manufacturing in Owings Mills, MD. It provides a contact form and the email address info@emitimaging.com for research inquiries.
The company offers instrumentation and services through an imaging platform for biological and drug research.
The privacy policy states that the Emit Imaging website is owned and operated by Emit Imaging Inc. The website includes company information, services, proprietary content, links, search capabilities, and other internet resources.
Emit Imaging develops high-resolution quantitative fluorescent imaging to bridge the gap between subcellular/cellular microscopy and whole-body imaging. The company addresses a critical lack of in vivo imaging tools for animal studies, complementing modalities like MRI, PET, and CT. Its technology aims to enhance life science research with precise, quantitative fluorescence imaging solutions.
EMIT IMAGING partners with the MIT Koch Institute to improve its Cryo-Fluorescence Tomography (CFT) technology. The collaboration integrates the Koch Institute’s cancer research expertise into EMIT’s workflow, aiming to boost accuracy and efficiency in disease studies. This project leverages the Koch Institute’s experience to refine CFT methods for broader applications in medical imaging.
EMIT Imaging names Dr. Matthew Silva as its new Chief Executive Officer. The appointment follows the company’s announcement of leadership changes. Silva brings expertise in medical imaging technologies to the role.
EMIT Imaging appoints Dr. Matthew Silva as its new Chief Executive Officer. The company specializes in advanced imaging technologies. Silva brings extensive experience in medical imaging and executive leadership to the role.
Emit Imaging develops high-resolution quantitative fluorescent imaging solutions to bridge a critical gap in life sciences. The company addresses the lack of high-resolution fluorescence imaging between subcellular/cellular microscopy and whole-body imaging modalities like MRI, PET, and CT. These tools aim to enhance in vivo (animal) studies with precise, quantitative data.